With no fresh increases in medicine prices, drugmakers in Egypt will continue to see their margins getting squeezed by high operational costs and by the health ministry-imposed price ceiling on end products. In Today’s Story, we shed some light on the cost equation for operations as borne by drugmakers and its impact on their profitability historically until end of June 2019. In our exercise, we compare the annual results of state-owned manufacturers by the end of 30 June 2019 against the trailing 12-month (TTM) results of the other companies ending their financial year in December (i.e. July 2018 to June 2019).
For more details, please read the full report below.

190902-Egyptian-Drugmakers-Are-Still-Hurt